XTalks

JUNE 15, 2022

Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Clinical Trial Results. Results from the PREVENT-19 pediatric expansion trial showed that the vaccine was also effective in adolescents aged 12 to 17 years. NVX-CoV2373 also includes an adjuvant called Matrix-M.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

MAY 1, 2023

This makes Qalsody the first approved treatment to target a genetic cause of ALS. Since SOD1 mutations were first identified as a cause of ALS 30 years ago, the familial ALS community has been searching for genetically targeted treatments. To date, over 200 mutations in the SOD1 gene have been associated with the development of ALS.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. So, this really validates what we already knew and now we have prospective results supporting that [from this trial].”.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

JUNE 10, 2024

The cause of psoriasis has yet to be fully understood, but scientists estimate its origins in genetic and environmental factors and immune dysregulation (where the body is unable to control its immune response). It is characterized by raised round or oval plaques lined with dry-looking silvery-white scales.

Immune Response 52

Immune Response Dermatology Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 10, 2020

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. Based on the encouraging Phase I data, Medicago says it plans to proceed with its Phase II/III trials.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

XTalks

JUNE 5, 2023

This interference may reduce the antiviral T-cell response or, in some cases, trigger the activation of unwanted pro-inflammatory T-cells, thus increasing the risk of severe lung infections. The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins. How Does Abrysvo Work? percent compared to a placebo.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.

Genome 104

Genome Genomics Medicine Development 104

XTalks

MAY 7, 2021

Novavax published the latest results from a Phase IIb clinical trial conducted in South Africa evaluating the safety and efficacy of NVX-CoV2373, appearing in the NEJM ’s May 6, 2021 issue. NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first, “original” strain of SARS-CoV-2.

Protein 97

Protein Vaccination Vaccine Trials 97

Roots Analysis

DECEMBER 11, 2022

As a result, t-cell immunotherapies market is expected to pick up pace in the coming years adn is anticipated to be the next goldmine in the life sciences industry. Various strategies that are used to redirect T-cells in order to elicit the desired immune response are given below: Source: Roots Analysis.

Marketing 40

Marketing Production Genetics Immune Response 40

XTalks

JUNE 9, 2022

What happens when the liver is unable to process bad cholesterol due to genetic factors? It is one of the common genetic causes of premature coronary heart disease. This particular platform creates fully human monoclonal antibodies from immunized mouse models — labeled VelocImmune mice — with a genetically humanized immune system.

Trials 52

Trials Antibody Genetics Gene 52

XTalks

MAY 30, 2024

CIDP is a rare autoimmune disorder where the body’s immune system mistakenly attacks its own tissues. The exact cause of this immune response is unknown, and there appears to be no identifiable genetic predisposition to CIDP. Researchers estimate that the incidence of CIDP in the US ranges from 0.8

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. Similarly, many clinical trials are going on to further strengthen the therapeutic pipeline for different Neurological Conditions. Parkinson’s Disease. a total of 2.8 per 100,000 population).

Marketing 98

Marketing Genetics Development Clinical Development 98

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Trials for both Juxtapid and Repatha made use of this endpoint to gain regulatory approval.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 18, 2021

Of important note is the aberrant immune response that occurs in patients with COVID-19, including the intensive release of cytokines (cytokine storm), which can make a patient infected with SARS-CoV2 more susceptible to contracting a bacterial respiratory infection.

Development 105

Development Bacteria Drugs Vaccination 105

Drug Discovery World

SEPTEMBER 6, 2022

And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. As is always the case with pharmaceuticals, the industry’s capabilities to manufacture and produce these potentially life-saving therapies will be of concern. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

Drug Discovery World

FEBRUARY 6, 2023

A case in point is the emerging omics and other high-throughput laboratory technologies that allow simultaneous profiling of genetic alterations in combination with profiling thousands of molecules in plasma, cell populations, or single cells.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

NOVEMBER 3, 2022

1 Emily was a seven-year-old girl who relapsed a second time following two years battling leukaemia, out of standard treatment options, and her life was saved by a CAR-T treatment in early clinical trial. They also do not have the potential of causing a severe immune response if they are administered to the wrong patient.

Gene Therapy 52

Gene Therapy Production Development Business Development 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52